Debra F. Eisenberg MS, PhD , Stuart J. Burstin MD , Christy Fang MS , Derek A. Misurski PhD
{"title":"美国商业保险人群中成人甲型肝炎的医疗保健利用和相关费用","authors":"Debra F. Eisenberg MS, PhD , Stuart J. Burstin MD , Christy Fang MS , Derek A. Misurski PhD","doi":"10.1016/j.ehrm.2012.03.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To examine the impact of acute hepatitis A<span> on health care utilization and cost in a commercially insured population.</span></p></div><div><h3>Study Design</h3><p><span>This observational, retrospective cohort study used medical and pharmacy claims data from January 1, 2004 through October 31, 2009. A matched control group consisted of patients without hepatitis A during the study period. </span>Descriptive statistics were used to assess differences between hepatitis A patients (cases) and controls.</p></div><div><h3>Results</h3><p>The case and control groups each contained 2331 patients. In the 12-month post-index period, 482 (20.7%) cases and 193 (8.3%; <em>P</em> < .0001) controls had inpatient (INP) hospitalizations (adjusted mean estimated costs [AMEC] $4433 and $1244 [<em>P</em><span> < .0001], respectively). Emergency department (ED) services occurred in 382 (16.4%) cases, versus 277 (11.9%; </span><em>P</em> < .0001) controls (AMEC $225 and $132 [<em>P</em> < .0001], respectively). The mean number of outpatient services (OUT) for cases was 21.5 (±22.1) versus 14.7 (±18.2) for controls, with AMEC $4132 and $2092, respectively. The mean number of physician visits was 9.1 (±9.9) and 5.5 (±7.4) for each group, respectively [AMEC $1025 vs. $577; <em>P</em> < .0001]. There were 20.13 (±24.1) and 19.37 (±24.5) pharmacy claims, with AMEC $1565 and $1115 (<em>P</em> < .0001), in cases and controls, respectively. Adjusted mean total estimated associated costs were $11,479 and $5323 (<em>P</em><span> < .0001), respectively. Multivariate regression results demonstrated that patients with hepatitis A have higher total medical costs even after adjusting for age, sex, comorbidities, pre-index cost, and hepatitis A vaccination.</span></p></div><div><h3>Conclusions</h3><p>Patients with hepatitis A had significantly higher health care resource utilization and costs during the 1-year post-index period, compared with controls.</p></div>","PeriodicalId":88882,"journal":{"name":"Health outcomes research in medicine","volume":"3 2","pages":"Pages e91-e101"},"PeriodicalIF":0.0000,"publicationDate":"2012-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ehrm.2012.03.003","citationCount":"1","resultStr":"{\"title\":\"Health Care Utilization and Associated Costs of Hepatitis A in Adults in a US Commercially Insured Population\",\"authors\":\"Debra F. Eisenberg MS, PhD , Stuart J. Burstin MD , Christy Fang MS , Derek A. Misurski PhD\",\"doi\":\"10.1016/j.ehrm.2012.03.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>To examine the impact of acute hepatitis A<span> on health care utilization and cost in a commercially insured population.</span></p></div><div><h3>Study Design</h3><p><span>This observational, retrospective cohort study used medical and pharmacy claims data from January 1, 2004 through October 31, 2009. A matched control group consisted of patients without hepatitis A during the study period. </span>Descriptive statistics were used to assess differences between hepatitis A patients (cases) and controls.</p></div><div><h3>Results</h3><p>The case and control groups each contained 2331 patients. In the 12-month post-index period, 482 (20.7%) cases and 193 (8.3%; <em>P</em> < .0001) controls had inpatient (INP) hospitalizations (adjusted mean estimated costs [AMEC] $4433 and $1244 [<em>P</em><span> < .0001], respectively). Emergency department (ED) services occurred in 382 (16.4%) cases, versus 277 (11.9%; </span><em>P</em> < .0001) controls (AMEC $225 and $132 [<em>P</em> < .0001], respectively). The mean number of outpatient services (OUT) for cases was 21.5 (±22.1) versus 14.7 (±18.2) for controls, with AMEC $4132 and $2092, respectively. The mean number of physician visits was 9.1 (±9.9) and 5.5 (±7.4) for each group, respectively [AMEC $1025 vs. $577; <em>P</em> < .0001]. There were 20.13 (±24.1) and 19.37 (±24.5) pharmacy claims, with AMEC $1565 and $1115 (<em>P</em> < .0001), in cases and controls, respectively. Adjusted mean total estimated associated costs were $11,479 and $5323 (<em>P</em><span> < .0001), respectively. Multivariate regression results demonstrated that patients with hepatitis A have higher total medical costs even after adjusting for age, sex, comorbidities, pre-index cost, and hepatitis A vaccination.</span></p></div><div><h3>Conclusions</h3><p>Patients with hepatitis A had significantly higher health care resource utilization and costs during the 1-year post-index period, compared with controls.</p></div>\",\"PeriodicalId\":88882,\"journal\":{\"name\":\"Health outcomes research in medicine\",\"volume\":\"3 2\",\"pages\":\"Pages e91-e101\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ehrm.2012.03.003\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health outcomes research in medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1877131912000109\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health outcomes research in medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877131912000109","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Health Care Utilization and Associated Costs of Hepatitis A in Adults in a US Commercially Insured Population
Objective
To examine the impact of acute hepatitis A on health care utilization and cost in a commercially insured population.
Study Design
This observational, retrospective cohort study used medical and pharmacy claims data from January 1, 2004 through October 31, 2009. A matched control group consisted of patients without hepatitis A during the study period. Descriptive statistics were used to assess differences between hepatitis A patients (cases) and controls.
Results
The case and control groups each contained 2331 patients. In the 12-month post-index period, 482 (20.7%) cases and 193 (8.3%; P < .0001) controls had inpatient (INP) hospitalizations (adjusted mean estimated costs [AMEC] $4433 and $1244 [P < .0001], respectively). Emergency department (ED) services occurred in 382 (16.4%) cases, versus 277 (11.9%; P < .0001) controls (AMEC $225 and $132 [P < .0001], respectively). The mean number of outpatient services (OUT) for cases was 21.5 (±22.1) versus 14.7 (±18.2) for controls, with AMEC $4132 and $2092, respectively. The mean number of physician visits was 9.1 (±9.9) and 5.5 (±7.4) for each group, respectively [AMEC $1025 vs. $577; P < .0001]. There were 20.13 (±24.1) and 19.37 (±24.5) pharmacy claims, with AMEC $1565 and $1115 (P < .0001), in cases and controls, respectively. Adjusted mean total estimated associated costs were $11,479 and $5323 (P < .0001), respectively. Multivariate regression results demonstrated that patients with hepatitis A have higher total medical costs even after adjusting for age, sex, comorbidities, pre-index cost, and hepatitis A vaccination.
Conclusions
Patients with hepatitis A had significantly higher health care resource utilization and costs during the 1-year post-index period, compared with controls.